AHA Coding Clinic® for HCPCS - 2012 Quarter 2; For Your Information
Reporting Update for the Administration of PROVENGE®
On January 6, 2012, The Centers for Medicare & Medicaid Services (CMS) reissued CR 7431, Transmittal 2380, for autologous cellular immunotherapy (PROVENGE ® ) treatment of metastatic prostate cancer with clarification regarding reporting the administration of PROVENGE ® separately. However, when CPT code 96365 , Intravenous infusion, for therapy, prophylaxis or diagnosis (specify substance or drug); initial, up to 1 hour, is reported with HCPCS code Q2043 , Sipuleucel-T, minimum of 50 million autologous cd54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion, an edit is caused which indicates that code 96365 is bundled with Q2043...
Subscribe or sign in to view the full article.
Article Overview
This article explains a Medicare/CMS reporting update affecting the administration of PROVENGE® in the context of metastatic prostate cancer. It is relevant to oncology, infusion administration, and medical billing/coding professionals who need to understand the scope of the CMS transmittal update, the associated editing issue, and the time frame addressed by the change.
Why This Topic Matters
Billing and coding teams need to stay current on CMS transmittals and claim-edit updates so they can interpret how administration services are handled alongside related immunotherapy reporting. Understanding this update helps readers assess whether the article applies to Medicare claims and infusion-related coding workflows.
Article Sections
-
CMS reporting update
Summarizes the Medicare/CMS communication that prompted the reporting clarification and the general claim-edit issue addressed in the update.
-
Revised editing for separate reporting
Describes the administration reporting context, the affected code set relationships, and the time period referenced by the update.
What You Will Learn
- The CMS reporting context for PROVENGE® administration claims
- How the article frames the related billing edit update
- The date range referenced by the CMS clarification
- The general claim-processing impact discussed in the update
Who Should Read This
- Medical coders
- Billing specialists
- Revenue cycle staff
- Oncology practice administrators
- Compliance professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com